Immunotherapy and radiation therapy for malignant pleural mesothelioma

Translational Lung Cancer Research
Evan W AlleyCharles B Simone

Abstract

Malignant pleural mesothelioma (MPM) is a particularly aggressive thoracic malignancy with limited survival following combination chemotherapy. As a result, there has been increased interested in immunotherapy for mesothelioma, both in the first-line and salvage settings. Early investigations of interleukin-2 (IL-2) and interferon alfa-2a/b have been limited by modest response rates and toxicity, whereas cytokine gene therapy is currently being investigated and shows early promise. The most prominent class of immunotherapies to be trialed with mesothelioma in the past half-decade has been immune checkpoint inhibitors (CPI). Early results are encouraging, particularly for agents targeting the PD-1/PD-L1 pathways. With the increasing recognition of the immune potential of mesothelioma, interest in the immunomodulatory properties of radiation therapy has emerged. The combination of immunotherapy and radiation therapy may allow for complimentary immunologic effects that can enhance antitumor response. This article reviews the existing literature on the efficacy of immunotherapy for MPM, describes the rationale for combining immunotherapy with radiation therapy, and discusses early literature on this treatment combination.

Citations

Jan 7, 2020·Médecine sciences : M/S·Manon DuboisLaurent Mortier
Aug 23, 2017·Medical Oncology·Alissar El ChediakYoussef H Zeidan
Apr 13, 2018·Frontiers in Oncology·Joe AbdoDevendra K Agrawal
Mar 25, 2019·Oncoimmunology·Pranav MurthyMichael T Lotze
Jan 14, 2021·Current Treatment Options in Oncology·Eric P Borrelli, Conor G McGladrigan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Related Papers

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
Anil VachaniSteven M Albelda
Annals of Cardiothoracic Surgery
Christopher CaoRebecca Harris
Annals of Oncology : Official Journal of the European Society for Medical Oncology
B CastagnetoM P Mencoboni
© 2022 Meta ULC. All rights reserved